Dexcom’s leadership said Thursday that the company has fixed problems with its flagship glucose monitor after reports of quality issues with its latest G7 sensor. The diabetes technology company has ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...
Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...
Dexcom is in seventh heaven: A year after its initial FDA submission, the diabetes tech maker has finally gotten the green light to begin rolling out its latest continuous glucose monitor system in ...
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim X2™ insulin pump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback